Tardive dyskinesia (TD) is a movement disorder typically caused by taking neuroleptic drugs. Treatment focuses on preventing the recurrence or persistence of symptoms. Tardive dyskinesia (TD) most ...

Tardive dyskinesia (TD) is an involuntary neurological movement disorder that is usually a side effect of certain dopamine receptor blocking drugs. It mainly affects the face but can also cause ...

CONDITION. I I’M A DIRECT SUPPORT PROFESSIONAL WITH THE ARC OF CARROLL COUNTY. BETHANY CHALMERS LOVES HELPING PEOPLE AND CONNECTING WITH OTHERS. BUT THOSE CONNECTIONS BECAME MORE CHALLENGING AFTER SHE ...

Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.

Tardive dyskinesia is a hyperkinetic movement disorder that causes faces to move involuntarily and abnormally. It is considered to be a drug-induced movement disorder. Movements often occur in the ...

Tardive Dyskinesia or TD is associated with certain prescription medications used to treat mental health or gastrointestinal conditions, and affects a broad range of people. It is characterized by ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription ...

TRENTON, N.J. (AP) — U.S. regulators have approved the first drug for treating a neurological syndrome that causes uncontrollable body movements that can also interfere with speech, swallowing and ...

Gray matter volume was compared among 3 groups, including healthy controls and those with schizophrenia with and without TD. Volume loss was greater in study participants with TD compared to controls ...

Neurocrine Biosciences has submitted a marketing approval application to the Food and Drug Administration for its drug to treat tardive dyskinesia, a movement disorder. The San Diego biotech also said ...

Tardive dyskinesia is a medication-induced movement disorder. It's typically caused by certain classes of medicines that block dopamine receptors in the brain. The typical offenders are a class of ...

This story also appeared on Everyday Heath's network site BP Hope. The U.S. Food and Drug Administration (FDA) has approved a new sprinkle formulation of valbenazine (Ingrezza) for individuals with ...